Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for
its duopoly status, says TD Cowen.
-
Novo Nordisk on Tuesday received a broker downgrade, with the analysts
arguing that its status as a duopoly in both diabetes and weight loss are
under threat.
50 minutes ago
